Undisclosed ERG degrader / Parabilis Medicines - LARVOL DELTA

Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program (Businesswire) - "Highlights of the data presented at AACR include: In mice implanted with prostate cancer cell-derived xenograft (CDX) tumors, administration of the ERG degrader produced >90% tumor ERG degradation through 7 days post dose. This corresponded to suppression of ERG’s downstream effects on target gene ARHGDIB; In both patient- and cell-line derived xenograft (PDX and CDX) models of TMPRSS2-ERG fusion prostate cancer, Parabilis’s ERG degrader significantly inhibited tumor growth; RNA sequencing expression analyses indicated that Parabilis’s ERG degrader downregulated Myc target genes; Parabilis’s ERG degrader uses Helicon technology to bind directly to the ERG protein and, through its attached E3 ligand, directs the ERG protein to the ubiquitin-proteasome pathway for degradation. The company anticipates entering IND-enabling toxicology studies in 2025."

Preclinical • Prostate Cancer

Parabilis Medicines to Present First Preclinical Data on ERG Degrader Program at AACR Annual Meeting (Businesswire) - "Parabilis Medicines (formerly Fog Pharmaceuticals)...announced the presentation of preclinical data on its first-in-class targeted protein degrader of ERG at the upcoming American Association for Cancer Research (AACR) Annual Meeting....The transcription factor ERG has been a long-recognized high-value target in prostate cancer, where ERG fusions have been implicated in 40-50% of all cases....Together Parabilis’s degraders of ERG and AR could potentially provide meaningful and differentiated therapeutic approaches to treat patients with metastatic castrate-resistant prostate cancer (mCRPC)."

Preclinical • Castration-Resistant Prostate Cancer